Judith Greciet

Last updated on 2017-09-28T10:06+0300.

About this image

sign

Quotes... Extracted quotes from

Judith Greciet souligné : "les biomarqueurs identifiés représentent des éléments importants qui seront intégrés dès la prochaine étude de phase 1b/2 d'AsiDNA en association que nous prévoyons d'initier dans les prochaines semaines grâce aux résultats intermédiaires d'activité et de tolérance satisfaisants obtenus dans l'étude DRIIV-1 en cours" External link

capital-FR Friday, January 4, 2019 11:27:00 AM EAT

Judith Greciet said : "This patent covering the combination of AsiDNA with any PARP inhibitor further reinforces our extensive patent portfolio, which is a key component of the value of AsiDNA. Our strong intellectual property position is an integral part of the Company's business model, which aims to progress disruptive compounds up to the most valuable clinical inflexion points and then to partner or license them, " External link

finanznachrichten-en Tuesday, December 18, 2018 11:12:00 PM EAT

Judith Greciet said : “This patent covering the combination of AsiDNA with any PARP inhibitor further reinforces our extensive patent portfolio, which is a key component of the value of AsiDNA. Our strong intellectual property position is an integral part of the Company’s business model, which aims to progress disruptive compounds up to the most valuable clinical inflexion points and then to partner or license them, ” External link

4-traders Tuesday, December 18, 2018 11:11:00 PM EAT

Judith Greciet said : "Our two drugs in development are based on the emerging areas of DNA-targeting and epigenetics, which are among the most promising approaches in cancer treatment research for both the pharmaceutical industry and academia today," External link

finanznachrichten-en Monday, October 2, 2017 9:40:00 AM EAT

Judith Greciet said : "These preclinical results widely open the potential of our two proprietary assets, strengthening Onxeo's position as innovation leader in DNA-targeting and epigenetics 1 , two mechanisms of action at the forefront of oncology research and highly sought after," External link

finanznachrichten-en Thursday, September 28, 2017 9:55:00 AM EAT

Judith Greciet said : "As we are approaching complete randomization in the ReLive study, we are, once again, encouraged by the DSMB's positive recommendation which confirmed the acceptable safety profile of Livatag® as regards to unexpected safety events. Enrolment is well on track and we should reach the 400 patients in the coming weeks, which comforts us in our planning of preliminary data announcement mid-2017. Livatag®'s potential to address the unmet medical need for HCC patients combined with the drug's favorable safety profile is a significant cornerstone in Onxeo's mission to develop innovative medicines for patients, providing patients with new therapeutic options, and a significant catalyst for the company value," External link

finanznachrichten-en Monday, November 21, 2016 8:40:00 PM EAT

Judith Greciet commented : “We are extremely pleased to announce this exclusive licensing agreement for Beleodaq®, and to have Pint Pharma as a strategic partner in South America. This is the second Beleodaq® licensing agreement, demonstrating our product’s commercial potential as well as its clinical value. We look forward to a close collaboration with Pint Pharma as we leverage their team’s strong expertise in this region to provide access to our treatment to a greater number of PTCL patients,” External link

businesswire Wednesday, July 27, 2016 7:57:00 PM EAT

Judith Greciet commented : "We are extremely pleased to announce this exclusive licensing agreement for Beleodaq®, and to have Pint Pharma as a strategic partner in South America. This is the second Beleodaq® licensing agreement, demonstrating our product's commercial potential as well as its clinical value. We look forward to a close collaboration with Pint Pharma as we leverage their team's strong expertise in this region to provide access to our treatment to a greater number of PTCL patients," External link

finanznachrichten-en Wednesday, July 27, 2016 7:55:00 PM EAT

Judith Greciet commented : "We are excited to partner with leading research institution such as RCSI for this preclinical program which should allow us to develop new compounds derived from belinostat. This will enable us to strengthen our portfolio while capitalizing on the experience already acquired with this product. Results of these researches are expected in the course of 2017," External link

finanznachrichten-en Thursday, July 7, 2016 9:34:00 PM EAT

Judith Greciet commented : “We are excited to partner with leading research institution such as RCSI for this preclinical program which should allow us to develop new compounds derived from belinostat. This will enable us to strengthen our portfolio while capitalizing on the experience already acquired with this product. Results of these researches are expected in the course of 2017,” External link

marketwatch Thursday, July 7, 2016 9:21:00 PM EAT

Judith Greciet commented : “We are excited to partner with leading research institution such as RCSI for this preclinical program which should allow us to develop new compounds derived from belinostat. This will enable us to strengthen our portfolio while capitalizing on the experience already acquired with this product. Results of these researches are expected in the course of 2017,” External link

businesswire Thursday, July 7, 2016 9:17:00 PM EAT



Key Titles and Phrases Count Lang Last Seen
chief executive officer23.33%EN10/02/201702/10/2017
ceo63.33%EN09/13/201713/09/2017
directrice générale5.00%FR09/12/201712/09/2017
directeur général5.00%FR11/29/201629/11/2016
direktør1.67%DA07/07/201607/07/2016
administrerende direktør1.67%DA07/07/201607/07/2016
Names Lang Count
Judith GrecietEN68.18%
Judith GrecietFR27.27%
Judith GrecietDA4.55%


 
Show/hide duplicate news articles.
<<10<12345678910>>>10
 
Show/hide duplicate news articles.
<<10<12345678910>>>10

Tools

Load latest edition

Friday, November 15, 2019

10:12:00 AM EAT

Languages Collapse menu...Expand menu...

Select your languages

af
am
ar
de
en
es
fr
ha
pt
rw
sw
all
Show additional languagesHide additional languages

Interface:

Legend Collapse menu...Expand menu...


Quotes... Explore Relations


EMM Visual Explorer


AfricaBrief

Judith Greciet

Last updated on 2017-09-28T10:06+0300.

About this image

sign

Quotes... Extracted quotes from

Judith Greciet souligné : "les biomarqueurs identifiés représentent des éléments importants qui seront intégrés dès la prochaine étude de phase 1b/2 d'AsiDNA en association que nous prévoyons d'initier dans les prochaines semaines grâce aux résultats intermédiaires d'activité et de tolérance satisfaisants obtenus dans l'étude DRIIV-1 en cours" External link

capital-FR Friday, January 4, 2019 11:27:00 AM EAT

Judith Greciet said : "This patent covering the combination of AsiDNA with any PARP inhibitor further reinforces our extensive patent portfolio, which is a key component of the value of AsiDNA. Our strong intellectual property position is an integral part of the Company's business model, which aims to progress disruptive compounds up to the most valuable clinical inflexion points and then to partner or license them, " External link

finanznachrichten-en Tuesday, December 18, 2018 11:12:00 PM EAT

Judith Greciet said : “This patent covering the combination of AsiDNA with any PARP inhibitor further reinforces our extensive patent portfolio, which is a key component of the value of AsiDNA. Our strong intellectual property position is an integral part of the Company’s business model, which aims to progress disruptive compounds up to the most valuable clinical inflexion points and then to partner or license them, ” External link

4-traders Tuesday, December 18, 2018 11:11:00 PM EAT

Judith Greciet said : "Our two drugs in development are based on the emerging areas of DNA-targeting and epigenetics, which are among the most promising approaches in cancer treatment research for both the pharmaceutical industry and academia today," External link

finanznachrichten-en Monday, October 2, 2017 9:40:00 AM EAT

Judith Greciet said : "These preclinical results widely open the potential of our two proprietary assets, strengthening Onxeo's position as innovation leader in DNA-targeting and epigenetics 1 , two mechanisms of action at the forefront of oncology research and highly sought after," External link

finanznachrichten-en Thursday, September 28, 2017 9:55:00 AM EAT

Judith Greciet said : "As we are approaching complete randomization in the ReLive study, we are, once again, encouraged by the DSMB's positive recommendation which confirmed the acceptable safety profile of Livatag® as regards to unexpected safety events. Enrolment is well on track and we should reach the 400 patients in the coming weeks, which comforts us in our planning of preliminary data announcement mid-2017. Livatag®'s potential to address the unmet medical need for HCC patients combined with the drug's favorable safety profile is a significant cornerstone in Onxeo's mission to develop innovative medicines for patients, providing patients with new therapeutic options, and a significant catalyst for the company value," External link

finanznachrichten-en Monday, November 21, 2016 8:40:00 PM EAT

Judith Greciet commented : “We are extremely pleased to announce this exclusive licensing agreement for Beleodaq®, and to have Pint Pharma as a strategic partner in South America. This is the second Beleodaq® licensing agreement, demonstrating our product’s commercial potential as well as its clinical value. We look forward to a close collaboration with Pint Pharma as we leverage their team’s strong expertise in this region to provide access to our treatment to a greater number of PTCL patients,” External link

businesswire Wednesday, July 27, 2016 7:57:00 PM EAT

Judith Greciet commented : "We are extremely pleased to announce this exclusive licensing agreement for Beleodaq®, and to have Pint Pharma as a strategic partner in South America. This is the second Beleodaq® licensing agreement, demonstrating our product's commercial potential as well as its clinical value. We look forward to a close collaboration with Pint Pharma as we leverage their team's strong expertise in this region to provide access to our treatment to a greater number of PTCL patients," External link

finanznachrichten-en Wednesday, July 27, 2016 7:55:00 PM EAT

Judith Greciet commented : "We are excited to partner with leading research institution such as RCSI for this preclinical program which should allow us to develop new compounds derived from belinostat. This will enable us to strengthen our portfolio while capitalizing on the experience already acquired with this product. Results of these researches are expected in the course of 2017," External link

finanznachrichten-en Thursday, July 7, 2016 9:34:00 PM EAT

Judith Greciet commented : “We are excited to partner with leading research institution such as RCSI for this preclinical program which should allow us to develop new compounds derived from belinostat. This will enable us to strengthen our portfolio while capitalizing on the experience already acquired with this product. Results of these researches are expected in the course of 2017,” External link

marketwatch Thursday, July 7, 2016 9:21:00 PM EAT

Judith Greciet commented : “We are excited to partner with leading research institution such as RCSI for this preclinical program which should allow us to develop new compounds derived from belinostat. This will enable us to strengthen our portfolio while capitalizing on the experience already acquired with this product. Results of these researches are expected in the course of 2017,” External link

businesswire Thursday, July 7, 2016 9:17:00 PM EAT



Key Titles and Phrases Count Lang Last Seen
chief executive officer23.33%EN10/02/201702/10/2017
ceo63.33%EN09/13/201713/09/2017
directrice générale5.00%FR09/12/201712/09/2017
directeur général5.00%FR11/29/201629/11/2016
direktør1.67%DA07/07/201607/07/2016
administrerende direktør1.67%DA07/07/201607/07/2016
Names Lang Count
Judith GrecietEN68.18%
Judith GrecietFR27.27%
Judith GrecietDA4.55%


<<10<12345678910>>>10
<<10<12345678910>>>10

Tools

Load latest edition

Friday, November 15, 2019

10:12:00 AM EAT


Quotes... Explore Relations


EMM Visual Explorer